Figure 4. Inhibition of human tumor growth by administrating rhEndostatin intravenously.

Hepatocellular carcinoma QGY-7703(A), A549 lung carcinoma(B), or Bcap37 breast cancer cells(C), were implanted to nude mice at the dosage of 6×10⁶ cells each, subcutaneously. Tumor-bearing mice were treated with either DDP (2 mg/kg/day) for successively 7 days(•), or rhEndostatin 10 mg/kg/day(▴), rhEndostatin 5 mg/kg/day(▾), and rhEndostatin 2.5 mg/kg/day(□) for successively 15 days. PBS(▪) was injected as the vehicle control. Results were presented as mean±SD (n = 10, each). Mice administered with rhEndostatin i.v. exhibited a significant reduction in tumor volume, compared with that in vehicle control group.